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Background
The prognosis of colorectal cancer patients has markedly 
improved over the last three decades because of enhanced 
surgical resection techniques, new multimodal therapy 
strategies and advancements in chemotherapy. In particular, 
5- year survival rate of rectal cancer patients has improved 
from 48% to 68% whereas survival of colon cancer patients 
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Abstract
The prognostic significance of bone marrow micro- metastases (BMM) in colon 
cancer patients remains unclear. We conducted a prospective cohort study with 
long- term follow- up to evaluate the relevance of BMM as a prognostic factor 
for disease free (DFS) and overall survival (OS) in stage I- III colon cancer 
patients. In this prospective multicenter cohort study 144 stage I- III colon cancer 
patients underwent bone marrow aspiration from both iliac crests prior to open 
oncologic resection. The bone marrow aspirates were stained with the pancy-
tokeratin antibody A45- B/B3 and analyzed for the presence of epithelial tumor 
cells. DFS and OS were analyzed using a Cox proportional hazard model and 
robust standard errors to account for clustering in the multicenter setting. Me-
dian overall follow- up was 6.2 years with no losses to follow- up, and 7.3 years 
in patients who survived. BMM were found in 55 (38%) patients. In total, 30 
(21%) patients had disease recurrence and 56 (39%) patients died. After adjust-
ing for known prognostic factors, BMM positive patients had a significantly 
worse DFS (hazard ratio [HR] 1.33; 95% confidence interval [95% CI]: 1.02-
1.73; P = 0.037) and OS (HR 1.30; 95% CI: 1.09-1.55; P = 0.003) compared 
to BMM negative patients. Bone marrow micro- metastases occur in over one 
third of stage I- III colon cancer patients and are a significant, independent 
negative prognostic factor for DFS and OS. Future trials should evaluate whether 
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did not increase accordingly (from 51% to 65%) [1]. This 
implies that rectal cancer patients nowadays show better 
disease outcomes than colon cancer patients [1]. Indeed 
up to 40% of stage I- III colon cancer patients develop 
disease recurrence within 5 years after operation [2]. As 
these patients showed no signs of distant metastases at 
the time of operation, disease recurrence is most likely 
a result of occult tumor cell dissemination prior to sur-
gery. This concept has recently been demonstrated in breast 
cancer patients, where dissemination of tumor cells into 
the blood stream as well as into the bone marrow (BM) 
has been identified as a source of disease recurrence [3, 
4]. Especially in early stage breast cancer patients these 
results are, however, still conflicting [5, 6]. Indeed most 
data on circulating tumor cells and bone marrow micro- 
metastases (BMM) are currently available for breast cancer 
patients. However, some evidence suggests that circulating 
tumor cells in the blood may have a prognostic signifi-
cance in colorectal cancer patients as well [7–9]. The role 
of BMM in colorectal cancer patients, however, is less 
clear, as there is only limited evidence from investigations 
with mostly short follow- up periods indicating a poorer 
prognosis for bone marrow positive patients [10–16]. 
Furthermore, the interpretation and comparison of these 
data is virtually impossible, as the studies were based on 
different protocols, used different antibodies and often 
analyzed colon and rectal cancer patients together. However, 
since there are significant differences in treatment strate-
gies as well as in survival improvement over the last 
decades between colon and rectal cancer patients, colon 
and rectal cancer should be considered as distinct disease 
entities, necessitating separate analysis.
Therefore, the objective of the present study was to 
evaluate the long- term prognostic significance of BMM 
in stage I-III colon cancer patients.
Patients and Methods
Study design
This prospective study was conducted at three academic 
and university- affiliated institutions in Switzerland 
(University Hospital Basel, Hospital Center Biel/Bienne, 
Cantonal Hospital Olten) between May 2000 and December 
2006. The study protocol was in accordance with the 
respective institutional guidelines for experimental inves-
tigation with human subjects as well as with the Declaration 
of Helsinki and was approved by the respective ethical 
committees of all participating centers. The study was 
registered at ClinicalTrials.gov (NCT00826579). The in- 
and exclusion criteria of the study have been previously 
reported [17]. Briefly, all patients with biopsy proven stage 
I-III colon cancer were eligible for study inclusion. 
Exclusion criteria were rectal cancers, stage IV disease, 
prior abdominal cancer surgery, history of other solid 
malignancies, documented allergy to isosulfan blue as well 
as pregnancy and breast feeding. Written informed consent 
was obtained from all patients before surgery.
Standard oncologic en- bloc resection (with appropriate 
lymphadenectomy) of the respective colon segment was 
performed. The primary tumor was staged according to the 
6th version of the tumor- node- metastasis (TNM) classifica-
tion system [18]. Adjuvant chemotherapy was offered to 
stage III patients and to stage II patients featuring high 
risk factors (i.e. less than 12 lymph nodes analyzed, lym-
phovascular or perineural invasion, T4 tumor, poorly dif-
ferentiated histology, or tumor perforation) as decided upon 
at the multidisciplinary tumor board conference. The par-
ticipants of the conference were blinded for the BM results, 
and BMM were therefore not taken into account for the 
decision whether to offer adjuvant chemotherapy or not. 
The follow- up period was calculated from the date of sur-
gery. A structured surveillance was performed according to 
national guidelines for surveillance after curative colon cancer 
resection [19, 20]. Follow- up examinations were carried out 
according to national guidelines for surveillance after cura-
tive colon cancer resection in all patients at 3 months 
intervals during the first year and at 6 months intervals 
thereafter, for a period of 5 years. The Swiss national guide-
lines for surveillance after curative colon cancer resection 
demand CT- scans (thorax/abdomen) in all patients at defined 
intervals of 12 months for a total of 5 years and CEA titers 
every three months for the first year and every six months 
for the second and third year. Subsequently, regular colo-
noscopy at 5 yearly intervals were performed. Development 
of local recurrence, distant metastases and death were con-
tinuously recorded. Contact was maintained with each 
patient’s general practitioner until the end of the study 
period to ensure complete follow- up.
Bone marrow collection and definitions
After induction of general anesthesia and prior to surgery, 
BM was aspirated from both iliac crests (5 mL each). The 
BM specimens were then processed as described previously 
by our group [5]. If one or more tumor cells were detected, 
the BM was considered positive. The pathologist was blinded 
regarding the primary tumor histology.
Statistical analyses
Baseline characteristics of all patients included in the analysis 
are summarized descriptively using median and interquartile 
range (IQR) or number and percentages. A separate baseline 
table is presented in the appendix for the patients excluded 
from the study (Table S1, online only).
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To estimate the effect of the BMM on disease free and 
overall survival, we plotted Kaplan Meier curves and used 
a Cox proportional hazard model taking into account the 
most relevant confounders. We used robust standard errors 
to adjust for potential clustering in the three study centers. 
The observation period in the overall survival (OS) analysis 
started on the day of surgery and lasted until the date of 
death irrespective of cause (failure) or until the last follow-
 up visit (censoring). The observation period in the disease- 
free survival (DFS) analysis started on the day of surgery 
and lasted until death irrespective of cause or the date of 
diagnosis of a recurrence, whichever occurred first, or until 
the last follow- up visit (censoring). In the disease- free sur-
vival analysis, recurrence or death due to any cause were 
considered as failure. The same observation period was 
considered in the analysis for the time to recurrence, in 
which recurrences or cancer- related deaths were considered 
as the event of interest and non- cancer- related deaths were 
considered as a competing event. We estimated subdistri-
butional hazard ratios in a semi- parametric model according 
to Fine and Gray and plotted the cumulative incidence 
function. Moreover, cause- specific hazard ratios were esti-
mated for the event of interest (recurrence or cancer- related 
death) as well as for the competing event (not-cancer- related 
death) in a Cox proportional hazard model, each with 
censoring the other event (i.e. not-cancer- related death was 
censored in the cause- specific model for the event of interest 
and recurrence or cancer- related death were censored in 
the cause- specific model for the competing event, respec-
tively). For these models a limited number of confounders 
(as compared to the model for OS and DFS) were taken 
into account due to the low number of events. Model 
diagnostics were performed investigating the proportional 
(subdistributional) hazard assumption and plotting scaled 
Schoenfeld residuals over time. All analyses were conducted 




Overall, 184 patients agreed to participate in the study. A 
total of 144 patients finally met the inclusion criteria. The 
study overview is shown in Figure 1. Clinical data and his-
tological findings of the included patients are listed in Table 1.
BMM were detected in 55 (38%) of the 144 patients. 
Of these BMM positive patients, 32 (58%) were node 
negative and 23 (42%) were node positive. The BM posi-
tivity rate showed little variation across the different AJCC 
Figure 1. CONSORT diagram. BMM, bone marrow micro- metastases.
Assessed for eligibility (n = 184)
Excluded (n = 40)
Stage IV disease not evident at the 
time of initial inclusion into the study (n 
= 21)
Punctio sicca (n = 6)
Operated during nights or weekends, 
no BM analysis available (n = 13)
Patients analyzed (n = 144)
Analyzed (n = 89)
Lost to follow-up (n = 0)
BMM negative (n = 89)
Node negative (n = 56)
Node positive (n = 33)
Analyzed (n = 55)
Lost to follow-up (n = 0)
BMM positive (n = 55)
Node negative (n = 32)
Node positive (n = 23) 
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stages (37% for stage I, 36% for stage II, 41% for stage 
III). A mean of 0.06 epithelial cells per 1*106 bone mar-
row cells (range 0.010- 1.714/1*106) were detected in the 
BM aspirates. In absolute numbers, between 1 and 95 
epithelial cells were counted per patient in their respective 
BM aspirates (mean 2.5).
In average, 23 lymph nodes were harvested and analyzed 
per patient (range 7-62). Only five patients showed less 
than 12 lymph nodes. In total, 48 (33%) patients received 
adjuvant chemotherapy (3.7% of patients in AJCC stage 
I, 18% in stage II, and 64% in stage III, respectively). In 
36% of stage III patients, chemotherapy was not admin-
istered because of advanced patient age or patient refusal. 
Adjuvant chemotherapy in stage I and II colon cancer 
was recommended according to interdisciplinary discussions 
and individual evaluation with the respective patients, based 
on the best available evidence [21]. Similarly, 21 (38%) 
of 55 BMM positive patients received adjuvant chemo-
therapy, with 10% of BMM positive patients in AJCC stage 
I, 18% in stage II, and 70% in stage III, respectively.
Time to recurrence
Follow- up could successfully be completed in all 144 
patients. During the follow- up period a total of 30 patients 
had a tumor recurrence and/or died from recurrent disease. 
These events occurred in 12 (22%) of 55 BM positive 
patients and in 18 (20%) of 89 BM negative patients. 
Median follow- up time for all patients was 6.2 years (IQR 
3.0-7.9 years). Median follow- up time for patients without 
event of interest was 7.3 years (IQR 6.2-10.8 years), and 
the corresponding follow- up time for patients with a com-
peting event was 2.9 years (IQR 0.6-5.7 years). In Fine 
and Gray’s multivariable subdistributional hazard model 
a positive BMM status was associated with a significant 
shorter time to recurrence (subdistributional hazard ratio 
[SHR] 1.17, 95% confidence interval [95%CI]: 1.03-1.34, 
P = 0.016) (Fig. 2, Table 2). Further independent prog-
nostic factors were male gender (SHR 2.77, 95% CI: 1.94-
7.92, P < 0.001) and positive nodal status (SHR 1.86,95% 
CI: 1.48-2.35, P < 0.001). The cause- specific hazard model 
for the event of interest shows consistent results (Table 2).







Age in years, median (IQR) 73.5 (66–79) 73 (66–78) 74 (66–81)
Gender, n (%)
Male 76 (53%) 47 (53%) 29 (53%)
Female 68 (47%) 42 (47%) 26 (47%)
BMI in kg/m2, median (IQR)* 26.0 (23.0– 28.4) 25.7 (22.8–28.4) 26.6 (23.7–28.6)
Localisation, n (%)
Right colon 61 (42%) 33 (37%) 28 (51%)
Left colon 24 (17%) 17 (19%) 7 (13%)
Sigmoid colon 59 (41%) 39 (44%) 20 (36%)
Tumor stage, n (%)
pT1 11 ( 8%) 7 (8%) 4 (7%)
pT2 22 (15%) 13 (15%) 9 (16%)
pT3 94 (65%) 59 (66%) 35 (64%)
pT4 17 (12%) 10 (11%) 7 (13%)
Nodal status, n (%)
pN0 88 (61%) 56 (63%) 32 (58%)
pN1 37 (26%) 21 (24%) 16 (29%)
pN2 19 (13%) 12 (13%) 7 (13%)
Lymphovascular invasion°, n (%)
Absent 114 (80%) 73 (82%) 41 (76%)
Present  29 (20%) 16 (18%) 13 (24%)
Tumor grading, n (%)
G1 - - - - - - 
G2 107 (74%) 71 (80%) 36 (65%)
G3 37 (26%) 18 (20%) 19 (35%)
Centre, n (%)
1 89 (62%) 55 (62%) 34 (62%)
2 40 (28%) 26 (29%) 14 (25%)
3 15 (10%)  8 (9%) 7 (13%)
BMM = bone marrow micro-metastases
BMI = body mass index
*3 missing values in BMI; °1 missing value in lymphovascular invasion
922 © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
C. T. Viehl et al.Bone Marrow Micrometastases Colon Cancer
Disease free survival analysis
For DFS analysis 61 (42%) events were recorded in 144 
patients. These events occurred in 28 (51%) of 55 BMM 
positive patients and in 33 (37%) of 89 BMM negative 
patients. Median follow- up time for DFS was 6.2 years 
(IQR 3.0-7.9 years). Median follow- up time for patients 
who survived (without recurrence) was 7.3 years (IQR 
6.2-9.1 years). Patients with BMM had a significant shorter 
DFS than patients without BMM in univariate analysis 
(P < 0.001, Fig. 3, Table 3).




Table 2. Hazard models for time to recurrence, cancer- related death and not- cancer- related death.
Univariate analysis Multivariable analysis
Exposures SHR (95% CI) P- value SHR (95% CI) P- value
Fine and Gray’s subdistributional hazard model for time to recurrence
BM pos. versus neg. 1.14 (0.82, 1.58) 0.439 1.17 (1.03, 1.34) 0.016
Age - per 10 years increase 1.04 (0.61, 1.76) 0.896 1.03 (0.57, 1.86) 0.917
Male versus female 2.63 (1.97, 3.52) <0.001 2.77 (1.94, 3.96) <0.001
Tumor stage T3/4 versus T1/2 2.93 (0.92, 9.36) 0.070 2.73 (0.94, 7.92) 0.064
Nodal status N1/2 versus N0 2.29 (2.09, 2.50) <0.001 1.86 (1.48, 2.35) <0.001
Univariate analysis Multivariable analysis
Exposures HR (95% CI) P- value HR (95% CI) P- value
Cause- specific hazard model for recurrence and cancer- related death
BM pos. versus neg. 1.27 (0.97, 1.67) 0.087 1.23 (1.11, 1.36) <0.001
Age - per 10 years increase 1.12 (0.66, 1.91) 0.662 1.14 (0.61, 2.13) 0.691
Male versus female 2.58 (1.87, 3.56) <0.001 2.50 (1.64, 3.80) <0.001
Tumor stage T3/4 versus T1/2 2.85 (0.88, 9.27) 0.081 2.53 (0.88, 7.28) 0.085
Nodal status N1/2 versus N0 2.41 (2.09, 2.79) <0.001 2.02 (1.64, 2.49) <0.001
Cause- specific hazard model for not- cancer- related death
BM pos. versus neg. 2.12 (1.82, 2.47) <0.001 1.72 (1.37, 2.15) <0.001
Age - per 10 years increase 2.78 (1.29, 5.96) 0.009 3.00 (1.18, 7.60) 0.021
Male versus female 0.92 (0.64, 1.34) 0.679 0.70 (0.62, 0.79) <0.001
Tumor stage T3/4 versus T1/2 0.60 (0.40, 0.91) 0.017 0.36 (0.15, 0.86) 0.022
Nodal status N1/2 versus N0 1.04 (0.76, 1.42) 0.818 1.92 (1.16, 3.16) 0.011
SHR, subdistributional hazard ratio, HR, hazard ratio.
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After adjusting for potential confounders in multivari-
able Cox regression analyses BMM was shown to be 
an independent negative prognostic factor for disease 
recurrence or death of any cause (HR 1.33, 95% CI: 
1.02-1.73, P = 0.037). Further independent negative 
prognostic factors for DFS were increased age (HR 1.76, 
95% CI: 1.57-1.96, P < 0.001), positive nodal status 
(HR 1.56, 95% CI: 1.11-2.20, P = 0.011), and lympho-
vascular invasion (HR 2.77, 95% CI: 1.87-4.11, 
P < 0.001) (Table 3).
Overall survival analysis
A total of 56 (39%) deaths of any cause out of the 144 
patients were recorded. Reasons for noncancer related 
deaths were cardial (n = 15), pulmonal (n = 6), other 
malignancy (n = 3), suicide (n = 1), cerebrovascular 
(n = 1), renal failure (n = 1), upper gastrointestinal bleed-
ing (n = 2) and unknown (n = 4). Median follow- up 
for OS was 6.2 years (IQR 3.8-8.2 years). Median follow-
 up time in those who survived was 7.3 years (IQR 
Figure 3. Kaplan–Meier survival curves for overall survival and disease- free survival for the covariates bone marrow (BM) negative and positive.
P < 0.001
P < 0.001
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6.2-9.1 years). Patients with BMM had a significant shorter 
OS than patients without BMM (P < 0.001, Fig. 3, Table 4).
After adjusting for potential confounders in multivari-
able Cox regression analyses, BMM remained a significant 
negative prognostic factor for OS (HR 1.30, 95% CI: 
1.09-1.55, P = 0.003). Further independent prognostic 
factors for OS were increased age (HR 2.04, 95% CI: 
1.69-2.46, P < 0.001), positive nodal stage (HR 1.24, 95% 
CI: 1.68-2.01, P < 0.001) and lymphovascular invasion 
(HR 2.81, 95% CI: 1.68-4.71, P < 0.001) (Table 4).
The differential effect of BMM in patients with pN0 
and pN1/2 was estimated in a post hoc analysis (Table 
S2). The risk for disease- free survival was higher in node 
positive patients (HR 1.71, 95% CI: 1.56-1.87, P < 0.001) 
than in node- negative patients (HR 1.27, 95% CI: 1.14-
1.41 P < 0.001). For overall survival, the added interaction 
term did not reach statistical significance.
Discussion
The objective of the present prospective multicenter study 
was to evaluate the long- term prognosis of BMM in colon 
cancer patients undergoing curative surgery. This inves-
tigation provides compelling evidence that BMM are an 
independent negative prognostic factor associated with a 
significant shorter time to recurrence, and with a signifi-
cant shorter overall and disease free survival. This finding 
is of cardinal importance as BMM were detected in more 
than one third of stage I-III colon cancer patients.
In the present investigation, BMM positive patients had 
a roughly 1.3- fold increased risk of disease recurrence 
and death compared to patients with a negative BM. BMM 
positivity clearly had a detrimental effect on survival time. 
The presence of BMM even in lymph node negative colon 
cancer patients indicates metastatic spread early in the 
course of the disease. The earlier appearance of events 
in BMM positive patients could therefore refer to an 
advanced, but histopathologically yet undetected tumor 
stage at the time of operation.
Using immunocytochemistry with a pancytokeratin anti-
body, BMM were detected in 38% of our patients. These 
results are in accordance with BMM detection rates of 
other solid cancer types, which were reported to be around 
35% [5, 14]. However, BMM detection rates in studies 
with colorectal cancer patients show a wide range. This 
is mainly due to different antibodies or detection methods 
used. These relevant technical differences make in- between 
comparisons of the reported results nearly impossible. 
While immunocytochemistry with the antibody A45- B/B3 
was performed in the present study which has already 
been successfully used by our group [5], others capitalized 
on magnetic activated cell sorting [22] or reverse 
transcription- polymerase chain reaction (rt- PCR), mainly 
of cytokeratin (CK)- 20 RNA [23–25]. These different 
Table 3. Uni- and multivariable Cox regression analysis for disease- free survival (n = 143 due to one missing value for lymphovascular invasion, LVI).
Univariate analysis Multivariable analysis
Exposures HR (95% CI) P- value HR (95% CI) P- value
BM pos. versus neg. 1.65 (1.54, 1.76) <0.001 1.33 (1.02, 1.73) 0.037
Age - per 10 years increase 1.67 (1.58, 1.76) <0.001 1.76 (1.57, 1.96) <0.001
Male versus female 1.49 (1.08, 2.04) 0.014 1.21 (0.94, 1.57) 0.146
Tumor stage T3/4 versus T1/2 1.09 (0.54, 2.20) 0.813 0.63 (0.30, 1.32) 0.219
Nodal status N1/2 versus N0 1.58 (1.41, 1.77) <0.001 1.56 (1.11, 2.20) 0.011
Grade 3 versus 2 2.04 (1.19, 3.48) <0.001 1.51 (0.74, 3.09) 0.259
LVI yes versus no 3.16 (2.21, 4.53) <0.001 2.77 (1.87, 4.11) <0.001
Table 4. Uni- and multivariable Cox regression analysis for overall survival (n = 143 due to one missing value for lymphovascular invasion, LVI).
Univariate analysis Multivariable analysis
Exposures HR (95% CI) P- value HR (95% CI) P- value
BM pos. versus neg. 1.66 (1.35, 2.04) <0.001 1.30 (1.09, 1.55) 0.003
Age - per 10 years increase 1.88 (1.70, 2.11) <0.001 2.04 (1.69, 2.46) <0.001
Male versus female 1.38 (0.89, 2.09) 0.149 1.10 (0.79, 1.54) 0.573
Tumor stage T3/4 vs T1/2 1.02 (0.42, 2.50) 0.957 0.55 (0.21, 1.42) 0.218
Nodal status N1/2 versus N0 1.60 (1.31, 1.95) <0.001 1.24 (1.68, 2.01) <0.001
Grade 3 versus 2 2.00 (1.11, 3.60) 0.022 1.51 (0.71, 3.19 0.284
LVI yes versus no 3.06 (1.97, 4.74) <0.001 2.81 (1.68, 4.71) <0.001
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methods have already been compared: In their study on 
metastatic colorectal cancer patients, Vogelaar et al. used 
the A45- B/B3 antibody as well as CK- 20 rt- PCR and 
reported a relevant difference in detection rates between 
the two techniques (33% by A45- B/B3 and 20% by CK- 
20) [23]. The CK- 20 detection rate was similarly low in 
the work by Koch et al. focusing on colorectal cancer 
patients with liver metastases. The authors therefore advo-
cated the use of A45- B/B3 [24]. In other studies, stage 
IV patients were included [12, 23, 25]. The usefulness of 
BMM detection in already metastasized patients is, how-
ever, questionable as BMM are generally regarded as a 
sign of tumor cell dissemination that takes place prior 
to surgery and serves rather as an indicator of occult 
disease than of an obvious metastatic situation.
The prognostic value of BMM in colon and rectal cancer 
patients has been discussed controversially for years. The 
discussion first came up in the early 1990s with the intro-
duction of immunocytochemical investigations with mono-
clonal antibodies that made the detection of histogenetically 
different cells possible. Beginning in the 1990s, first studies 
on colorectal cancer patients reported higher disease recur-
rence rates when BMM were present at time of surgery [26, 
27]. However, because of rather small sample sizes and short 
follow- up times these studies did not have an impact on 
daily clinical practice. More recently, one group demonstrated 
a detrimental effect of BMM in a cohort of 235 colorectal 
cancer patients (with 32% rectal cancer patients) [26]. The 
authors of this study, however, reported a very low BMM 
detection rate of 12% and 17%, using two different antibod-
ies and detection techniques. In contrast to such suggestive 
evidence, O’Connor et al. could not detect an impact on 
DFS in their cohort of 34 colorectal cancer patients (seven 
with BMM) which is quite likely due to the small sample 
size [27]. In their most recently published study, Vogelaar 
et al. could not detect a statistically significant association 
between disseminated tumor cells in the bone marrow and 
disease outcome in 125 patients with primary colorectal 
cancer. However, the BMM detection rate (18%) was sig-
nificantly lower than in the here presented study and the 
smaller patient cohort may be responsible for the nonsig-
nificant results [28]. This is also reflected by a much wider 
95% confidence interval for overall survival (0.45-2.09) and 
disease- free survival (0.35-1.82) compared to our results. It 
is important to note that most studies did not distinguish 
between colon and rectal cancer patients. Only one study 
so far was focusing on colon cancer patients exclusively and 
the authors identified BMM as an independent negative 
prognostic factor for survival [29]. However, this study 
included 20% stage IV patients receiving palliative surgery 
and the mean observation time of 39 months was rather 
short, preventing a clear statement on disease recurrence 
and OS. In this context the publication by Kienle et al. is 
relevant as the authors reported a significantly lower detec-
tion rate of BMM in rectal cancer patients after administra-
tion of neoadjuvant chemoradiation (16.7%) compared to 
patients without preoperative treatment (33%) [30]. This 
finding strongly advocates for a clear separation of colon 
and rectal cancer patients in clinical trials, as many rectal 
cancer patients nowadays receive preoperative therapy and 
are biologically different with better prognosis compared to 
colon cancer. Interestingly, in the here presented study BMM 
were more common in patients with right- sided colon cancer. 
There is an ongoing discussion if tumor localization itself 
has a prognostic meaning in patients with colon cancer. 
The majority of existing studies report poorer survival for 
right- sided colon cancer, compared to left- sided [31, 32]. It 
has been speculated that a later detection due to the right- 
sided localization or differences in embryologic origin and 
fecal exposure may play a role. A most recently published 
study however questions the right- sided survival disadvantage 
as the authors identified that prognostic differences between 
right- and left- sided colon cancer may not be real and seem 
to occur due to differences regarding confounders [33]. It 
therefore remains a matter of debate if localization of the 
primary tumor will be of prognostic significance. However, 
due to the limited sample size the present study cannot 
answer why BMM appeared more often in patients with 
right sided colon cancer. This question should be explored 
in future research planned to investigate this hypothesis.
An important strength of our study is that we included 
only stage I–III colon cancer patients resulting in a much 
more homogeneous patient sample. To differentiate 
whether there is an association between nodal status and 
BMM, we performed a not- prespecified explanatory analysis 
that provided some evidence that the negative effect of 
BMM on disease- free survival seems to be more pro-
nounced in patients with pN1/pN2 compared to pN0. 
However, tests for interaction have a low power and the 
interaction term did not reach statistical significance for 
overall survival (Table S2). This question has therefore 
to be further explored in a subsequent study.
Another major strength of the present study is its long 
follow- up time exceeding 6 years without any patients 
who were lost to follow- up.
However, we would also like to acknowledge the limita-
tions of our study. A major drawback in clinical cancer 
studies lies in the possibility that competing events such 
as not- cancer related death may produce misleading results. 
It is well known that competing events occur frequently 
in clinical trials and that the standard Cox proportional 
hazards model is not an entirely adequate analysis in the 
presence of such competing events. We therefore used a 
Fine and Gray subdistributional hazard model to estimate 
separately the risk for the event of interest and the com-
peting event. Furthermore, the present investigation is a 
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prospective cohort study and potential unmeasured con-
founding cannot be excluded. However, the baseline char-
acteristics between included and excluded patients are 
comparable in our study and the presence of a relevant 
bias is therefore unlikely. Moreover, the sample size limited 
the statistical model in this study. To avoid collinearity, 
the effect of chemotherapy was therefore not included in 
the analysis.
And finally, genetic testing was not a state of the art 
procedure at the time of patient inclusion and we can 
therefore not report on these differences. This would have 
been interesting especially for the comparison of right- 
versus left- sided colon cancer as discussed above.
In conclusion, our study provides compelling evidence 
that BMM are associated with a significant shorter time 
to recurrence, and with a significantly worse DFS and OS 
in stage I- III colon cancer patients. Bone marrow micro- 
metastases were identified as an independent negative prog-
nostic factor for DFS and OS. This is particularly relevant 
as the presence of BMM represents a frequent phenomenon 
occurring in over one third of stage I- III colon cancer 
patients. As aspiration of BM is simple, BM analysis for 
micro- metastasis should be incorporated in future trials to 
evaluate whether node- negative colon cancer patients with 
BMM benefit from adjuvant chemotherapy.
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Table S1: Baseline characteristics of all patients excluded 
from the analysis (n = 40): 21 patients had stage IV 
disease and in additional 19 patients no BM was harvested 
or usable (six punctio sicca, 11 patients operated during 
night or weekend, one patient refused bone marrow aspi-
ration, one technical problem with analysis of bone mar-
row aspiration)
Table S2: Post hoc analysis of the multivariable model 
by adding the interaction term node negative vs. node 
positive1.
